Palmitoylethanolamide against cancer and protects against chemo-therapy induced damage of nerves

In 2011 the group of Professor Cruccu of the university of Rome published a paper showing that PEA could reduce the harm done by chemotherapy to nerves. Pain was less and nerve-functions were better, if patients with cancer and chemotherapy were also treated with palmitoylethanolamide (1200 mg/day).

This idea, to protect important cells against the damage done by chemotherapy has been brought forward in 1975 already. As this paper has great value, and is very unknown and difficult to find we document the ideas in that paper in this article.

Palmitoylethanolamide against chemotherapy damage

The paper started with the remark that PEA is a specific anti-toxic agent and that its use to counteract toxicity of chemotherapy would be interesting:

Schermafbeelding 2013-02-21 om 15.37.30

And after testing a variety of chemotherapeutic agents in various coctails, the results showed a clear add-on effect of PEA, and this even had positive impact on the survival time after the emergence of the cancer, as can be easily seen via the survival plot enclosed.

PEA in cancer and chemotherapyThe authors stipulated that the presence of PEA helped to reach a higher level of chemotherapy, without the troublesome dose-limiting side effects.

PEA enhances chemotherapy in cancer

In te final graph the effects of PEA were very clear: less mortality due to side effects, and less mortality due to the cancer itself. Results under speak for themselves. Based  on this animal study and the recent data in patients with cancer, PEA seems a very wise addition, decreasing side effects of chemo-therapy, and enhancing the therapeutic effects against the cancer.


PEA protects against side effects of chemo Schermafbeelding 2013-02-21 om 15.58.04

These effects have been duplicated in 2002, in the study:  Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems., by De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V. In: Fundam Clin Pharmacol. 2002 Aug;16(4):297-302.

With 2 preclinical studies and one clinical study, all pointing in the same direction, PEA needs to be considered by patients and doctors if patients are being treated with chemo-therapy.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: